Your browser is no longer supported. Please, upgrade your browser.
Settings
SHPG Shire plc daily Stock Chart
SHPG [NASD]
Shire plc
Index- P/E28.19 EPS (ttm)5.31 Insider Own0.10% Shs Outstand303.97M Perf Week6.96%
Market Cap45.53B Forward P/E9.35 EPS next Y16.03 Insider Trans0.00% Shs Float299.48M Perf Month3.65%
Income1.62B PEG2.77 EPS next Q3.89 Inst Own21.20% Short Float0.69% Perf Quarter4.96%
Sales14.82B P/S3.07 EPS this Y-65.50% Inst Trans5.16% Short Ratio1.81 Perf Half Y-18.96%
Book/sh107.98 P/B1.39 EPS next Y6.94% ROA2.40% Target Price216.21 Perf Year-13.25%
Cash/sh- P/C- EPS next 5Y10.17% ROE5.30% 52W Range137.17 - 192.15 Perf YTD-12.09%
Dividend0.92 P/FCF- EPS past 5Y-12.80% ROI2.10% 52W High-22.05% Beta1.62
Dividend %0.61% Quick Ratio0.50 Sales past 5Y22.30% Gross Margin69.70% 52W Low9.19% ATR3.99
Employees23906 Current Ratio1.00 Sales Q/Q7.10% Oper. Margin15.70% RSI (14)57.56 Volatility2.65% 1.85%
OptionableYes Debt/Eq0.63 EPS Q/Q247.70% Profit Margin11.00% Rel Volume0.74 Prev Close144.83
ShortableYes LT Debt/Eq0.55 EarningsOct 27 BMO Payout5.60% Avg Volume1.14M Price149.78
Recom1.90 SMA204.59% SMA500.65% SMA200-8.95% Volume837,084 Change3.42%
Nov-14-17Upgrade Liberum Hold → Buy
Oct-19-17Initiated FBR & Co. Buy $201
Oct-11-17Reiterated RBC Capital Mkts Outperform $213
Aug-17-17Initiated Evercore ISI Outperform $196
Jun-16-17Initiated Cantor Fitzgerald Overweight $222
Jun-09-17Reiterated Jefferies Buy $239 → $216
Jun-01-17Downgrade Liberum Buy → Hold
May-26-17Downgrade Bernstein Outperform → Mkt Perform
May-19-17Downgrade HSBC Securities Hold → Reduce
Mar-09-17Initiated Liberum Buy
Dec-02-16Initiated Societe Generale Buy
Sep-26-16Downgrade HSBC Securities Buy → Hold
Jun-03-16Reiterated Jefferies Buy $223 → $262
May-26-16Initiated Stifel Buy $230
May-06-16Initiated Liberum Buy
Feb-26-16Initiated Cantor Fitzgerald Buy
Feb-10-16Upgrade RBC Capital Mkts Sector Perform → Outperform $240 → $240
Feb-10-16Initiated Guggenheim Neutral
Jan-15-16Upgrade BofA/Merrill Neutral → Buy
Jan-12-16Upgrade Credit Suisse Neutral → Outperform
Nov-20-17 11:40AM  Is Shire Bleeding Out? Barrons.com
08:01AM  Shire plc : Directorate change GlobeNewswire
07:05AM  Why Shire plc (LSE:SHP) Could Be A Buy Simply Wall St.
Nov-17-17 09:05AM  Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval Zacks
Nov-14-17 10:09AM  Shire Gets Positive CHMP Opinion for Hemophilia A Drug Zacks
Nov-13-17 01:01AM  CHMP recommends EU marketing authorization for ADYNOVI® for adults and adolescents with Hemophilia A GlobeNewswire
Nov-10-17 07:01AM  Shire presentations at ASH 2017 highlight commitment to furthering research and innovation in Hematology and Oncology GlobeNewswire
Nov-07-17 06:02AM  The Only 3 Big Pharma Companies Growing Market Share Motley Fool
Nov-03-17 12:32PM  ETFs with exposure to Shire Plc : November 3, 2017 Capital Cube
06:01AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
Nov-02-17 10:03AM  FTSE gains after dovish BoE rate hike, domestic banks drop Reuters
07:50AM  Earnings Review and Free Research Report: Eli Lillys Adjusted EPS Increased 19% ACCESSWIRE
Nov-01-17 08:02AM  Shire plc : Total voting rights GlobeNewswire
Oct-30-17 11:53AM  Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong Zacks
05:49AM  Fund manager, analysts make the case for this loathed pharma stock MarketWatch
Oct-27-17 01:05PM  Shire to sell 100-employee Milford site as part of manufacturing slim-down American City Business Journals
11:01AM  Shire to make genetic disease drug itself to secure supply Reuters
07:28AM  Shire beats 3Q profit forecasts Associated Press
07:02AM  Shire plc : 3rd Quarter Results GlobeNewswire
Oct-26-17 12:16PM  Allergan (AGN) to Report Q3 Earnings: What's in the Cards? Zacks
02:02AM  Shire Receives European Approval for Label Extension of FIRAZYR® (icatibant injection) for the Symptomatic Treatment of Acute HAE Attacks in Paediatric Patients GlobeNewswire
Oct-25-17 07:01AM  Shire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for the Treatment of Hemophilia A GlobeNewswire
Oct-23-17 11:03AM  ETFs with exposure to Shire Plc : October 23, 2017 Capital Cube
Oct-19-17 09:18AM  Create the Soundtrack to Your Unique Day with "Compose Your Life" PR Newswire
Oct-17-17 09:27AM  Why Shire plc (LSE:SHP) Delivered An Inferior ROE Compared To The Industry Simply Wall St.
Oct-16-17 10:02AM  Shire's New Formulation of Oncaspar Gets CHMP Recommendation Zacks
Oct-13-17 02:06AM  Shire plc : New Formulation of ONCASPAR® (pegaspargase) Receives Positive CHMP Opinion in Europe for Patients with Acute Lymphoblastic Leukemia (ALL) GlobeNewswire
Oct-10-17 11:49AM  ETFs with exposure to Shire Plc : October 10, 2017 Capital Cube
Oct-09-17 09:54AM  Shire Plc :SHPG-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017 Capital Cube
Oct-05-17 07:02AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
Oct-03-17 07:02AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
01:04AM  Shire Alleges Allergan Blocked Drug From Medicare Contracts The Wall Street Journal
Oct-02-17 02:00PM  Shire Alleges Allergan Blocked Drug From Medicare Contracts The Wall Street Journal
12:14PM  Shire sues Allergan in U.S. over dry eye drug Reuters
09:02AM  Shire plc : Total voting rights GlobeNewswire
Sep-29-17 10:36AM  Should You Sell Shire plc (LSE:SHP) At £37.78? Simply Wall St.
09:32AM  Shire Plc : SHPG-US: Dividend Analysis : September 08th, 2017 (record date) : By the numbers : September 29, 2017 Capital Cube
Sep-25-17 11:42AM  Why Allergan is Jumping Barrons.com
Sep-21-17 09:50AM  Is Shire plc (SHPG) a Suitable Value Stock? Zacks
Sep-18-17 10:00AM  Neos Therapeutics ADHD Drug Adzenys Receives Approval in US Zacks
Sep-15-17 07:39AM  Whats Coopermans View on Shire? Market Realist
Sep-12-17 04:38PM  Top Research Reports for Disney, Kraft Heinz & CVS Health Zacks
Sep-08-17 09:53AM  Alnylam Shares Plunge on Patient Death, Dosing Suspended Zacks
Sep-07-17 01:03PM  Here's Why Shire PLC Stock Fell 10% in August Motley Fool
Sep-01-17 06:32AM  Shire plc : Total voting rights GlobeNewswire
Aug-30-17 07:20AM  Corporate News Blog - Sanofi Completes Acquisition of Vaccines Biotechnology Company, Protein Sciences ACCESSWIRE
Aug-24-17 10:08AM  Roche (RHHBY) Hemophilia A Drug Granted Priority Review Zacks
Aug-23-17 07:02AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
05:33AM  Shire chief financial officer joins Boston ag-tech startup American City Business Journals
Aug-22-17 11:32AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
Aug-21-17 01:29PM  UPDATE: Shire: There Goes the CFO! Barrons.com
09:01AM  Shire plc Director and Senior Management Changes GlobeNewswire
Aug-16-17 05:18PM  Shire Files Marketing Application for Lifitegrast in Europe Zacks
Aug-15-17 06:00AM  Shire applies for European approval of potential blockbuster eye drop American City Business Journals
04:55AM  Shire Gains as it Seeks European Approval For Dry Eye Treatment TheStreet.com
02:02AM  Shire announces submission of lifitegrast Marketing Authorization Application for treatment of dry eye disease in Europe GlobeNewswire
Aug-09-17 09:17AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
Aug-04-17 09:47AM  Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View Zacks
02:52AM  Shire plc : Half-yearly report GlobeNewswire
Aug-03-17 02:29PM  Shire's ADHD Spinoff Idea Is Shaky Bloomberg
02:10PM  [$$] Lombard: Impatient Shire boss waits for market to catch up Financial Times
02:10PM  Shire Acq Inv Ireland Designated Activity Co -- Moody's: Shire's evaluation of neuroscience franchise credit negative Moody's
09:58AM  [$$] Shire Mulls Spinning-off or Selling Neuroscience Unit The Wall Street Journal
09:42AM  Shire tops Street 2Q forecasts Associated Press
07:53AM  Shire Surges on Baxalta Synergies and Strong Earnings Momentum TheStreet.com
07:10AM  Investor Network: Shire PLC to Host Earnings Call ACCESSWIRE
07:02AM  Shire plc : Shire reports strong Q2 2017 operating results and cash flow GlobeNewswire
Aug-01-17 07:02AM  Shire plc : Total voting rights GlobeNewswire
Jul-26-17 04:29PM  Shire Stock Rising on Takeover Talks TheStreet.com
07:01AM  Gap In Perceived and Actual Rates Of Prescription Stimulant Misuse, Abuse and Diversion Found Among College Students GlobeNewswire
Jul-20-17 11:08AM  New Strong Sell Stocks for July 20th Zacks
Jul-18-17 07:02AM  Shire plc : Notice of Results GlobeNewswire
07:02AM  Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody GlobeNewswire
Jul-16-17 08:18AM  [$$] Shire boss says share price at odds with drugs pipeline Financial Times
Jul-13-17 09:30AM  The Zacks Analyst Blog Highlights: Merck, Eli Lilly, Celgene, Gilead Sciences and Shire Zacks
08:13AM  5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings Zacks
Jul-12-17 06:01PM  A Cancer Breakthrough Near FDA Approval Has a Costly Side Effect Bloomberg
09:15AM  Analyst: Shire Shares Should Rebound, But Sustained Rally Unlikely Benzinga
Jul-11-17 08:39PM  Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run TheStreet.com
04:19PM  Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data Zacks
Jul-10-17 09:47AM  Shire, Roche slug it out in billion-dollar haemophilia drug battle Reuters
Jul-07-17 09:42AM  Shire Completes NDA Filing for Hemophilia Drug with FDA Zacks
Jul-06-17 07:01AM  Shire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of Hemophilia A GlobeNewswire
02:02AM  Shire plc : Additional Listing GlobeNewswire
Jul-05-17 08:03AM  3 Reasons Sizzling-Hot Bioverativ Stock Can Go Even Higher Motley Fool
Jul-03-17 08:32AM  Shire plc : Director/PDMR Shareholding GlobeNewswire
07:01AM  Shire plc : Total voting rights GlobeNewswire
Jun-26-17 09:30AM  The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk Zacks
Jun-23-17 08:02AM  SHIRE TO PRESENT NEW DATA AT ISTH 2017 TO ADVANCE THE STANDARD OF CARE IN HEMOPHILIA GlobeNewswire
07:42AM  Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod Zacks
Jun-22-17 10:54AM  Shire (SHPG) Receives MAA Validation for Veyvondi by EMA Zacks
09:36AM  Biotech Movers: Shire, Bellicum, Organovo TheStreet.com
01:00AM  Shire Announces EMA Validation of Veyvondi Marketing Authorization Application for Treatment of Von Willebrand Disease PR Newswire
Jun-21-17 10:52AM  Shire's (SHPG) ADHD Drug Mydayis Receives Approval in US Zacks
10:25AM  Shire wins FDA approval for new ADHD drug American City Business Journals
Jun-20-17 07:19PM  Shire's long-acting ADHD drug wins U.S. approval Reuters
06:48PM  Shire plc: U.S. FDA Approves Mydayis (Mixed Salts of a Single-Entity Amphetamine Product) - A New Once-Daily Option for ADHD Symptom Control in Patients 13 Years and Older PR Newswire
Jun-19-17 09:45AM  Could Shire PLC (SHPG) Be a Great Stock for Value Investors? Zacks
09:02AM  Do You Really Want to Love Your Medicines? Fortune
Jun-16-17 10:54AM  Valeant: Stop Looking in the Rearview Mirror! Barrons.com
Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.